These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 17596715)
1. Caenorhabditis elegans as a model system for Parkinson's disease. Schmidt E; Seifert M; Baumeister R Neurodegener Dis; 2007; 4(2-3):199-217. PubMed ID: 17596715 [TBL] [Abstract][Full Text] [Related]
2. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. Harrington AJ; Hamamichi S; Caldwell GA; Caldwell KA Dev Dyn; 2010 May; 239(5):1282-95. PubMed ID: 20108318 [TBL] [Abstract][Full Text] [Related]
3. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. Locke CJ; Fox SA; Caldwell GA; Caldwell KA Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411 [TBL] [Abstract][Full Text] [Related]
4. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need. Nass R; Merchant KM; Ryan T Mol Interv; 2008 Dec; 8(6):284-93. PubMed ID: 19144901 [TBL] [Abstract][Full Text] [Related]
5. [Study of molecular mechanism of anti-Parkinson's disease traditional Chinese medicine using model of Caenorhabditis elegans]. Wang X; Wang X; Gao H; Wang D Zhongguo Zhong Yao Za Zhi; 2010 Mar; 35(5):661-3. PubMed ID: 20506834 [TBL] [Abstract][Full Text] [Related]
6. Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease. Jadiya P; Chatterjee M; Sammi SR; Kaur S; Palit G; Nazir A Biochem Biophys Res Commun; 2011 Sep; 413(2):306-10. PubMed ID: 21889494 [TBL] [Abstract][Full Text] [Related]
7. Caenorhabditis elegans: a useful tool to decipher neurodegenerative pathways. Johnson JR; Jenn RC; Barclay JW; Burgoyne RD; Morgan A Biochem Soc Trans; 2010 Apr; 38(2):559-63. PubMed ID: 20298221 [TBL] [Abstract][Full Text] [Related]
9. C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Link CD Exp Gerontol; 2006 Oct; 41(10):1007-13. PubMed ID: 16930903 [TBL] [Abstract][Full Text] [Related]
10. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease. Jadiya P; Khan A; Sammi SR; Kaur S; Mir SS; Nazir A Biochem Biophys Res Commun; 2011 Oct; 413(4):605-10. PubMed ID: 21925152 [TBL] [Abstract][Full Text] [Related]
11. Modeling neurodegenerative diseases in Caenorhabditis elegans. Li J; Le W Exp Neurol; 2013 Dec; 250():94-103. PubMed ID: 24095843 [TBL] [Abstract][Full Text] [Related]
12. C. elegans as a genetic model system to identify Parkinson's disease-associated therapeutic targets. Vistbakka J; VanDuyn N; Wong G; Nass R CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):957-64. PubMed ID: 23244419 [TBL] [Abstract][Full Text] [Related]
13. Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD. Mandel SA; Fishman T; Youdim MB Parkinsonism Relat Disord; 2007; 13 Suppl 3():S242-7. PubMed ID: 18267243 [TBL] [Abstract][Full Text] [Related]
14. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. McFarlane D Ageing Res Rev; 2007 May; 6(1):54-63. PubMed ID: 17374512 [TBL] [Abstract][Full Text] [Related]